AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 1Trial registry
PET-CT Scans in Multiple Sclerosis Patients
A Phase 1 exploratory study evaluated the use of entire-body PET-CT scans to monitor demyelination in 20 MS patients. The aim was to assess differences in radiotracer activity in white matter compared to healthy subjects.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
This study could enhance understanding of how demyelination progresses in MS, potentially improving future monitoring and treatment strategies.
What this does not prove
No results from this study have been posted yet and planned methods do not confirm the outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 20 · estimated
- Randomised
- No
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
- Trial registrationEntire-body PET Scans for Multiple Sclerosis ↗
Supporting passages (11)
study phase"EARLY_PHASE1"
study design"studyType": "INTERVENTIONAL"
subjects"label": "Amended Protocol for Exploratory Study of Entire-body PET Scans for Multiple Sclerosis (EPSMS)",
sample size"count": 20
sample size basis"type": "ESTIMATED"
randomized"allocation": "NON_RANDOMIZED"
regulatory approval"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": true
intervention"name": "Entire-body PET-CT scans"
primary endpoint"measure": "Entire-body PET imaging of demyelination of peripheral and central nervous system"
findings"detailedDescription": "To collect exploratory data using the most recent PET-CT scanners with their increased detection sensitivity and spatial resolution for the evaluation of F18-florbetapir radiopharmaceutical uptake in the nervous system of the entire body with special attention to correlation of radiotracer activity levels in the myelinated, demyelinated, or remyelinated white matter of multiple sclerosis (MS) patients compared to normal healthy subjects.
limitationsNo results are posted.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.